Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

on), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

About Bayer HealthCareThe Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials.  Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 15.9 billion (2009), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany.  The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.  Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.  Bayer HealthCare has a global workforce of 53.400 employees and is represented in more than 100 countries.  Find more information at www.bayerhealthcare.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Australia, May 14 Progen,Pharmaceuticals Limited (ASX:PGL; Nasdaq: ... enrolment in the phase 1 dose-escalation study,of its ... with advanced cancer., Progen has commenced development ... Company,s polyamine program - following its acquisition of,Cellgate, ...
... for cervical cancer prevention, GRAZ, Austria, May ... show that GlaxoSmithKline (NYSE: GSK ) cervical,cancer ... antibodies against the two most common cervical cancer-causing,human ... is the longest,duration of sustained neutralizing antibody levels ...
Cached Medicine Technology:Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6
(Date:4/24/2014)... three survivors of critical illness, according to a ... Medicine , and the majority of patients experience ... is one of the largest studies to investigate ... care survivors, according to lead author James Jackson, ... a significant public health issue, with roughly 5 ...
(Date:4/24/2014)... National Science Foundation has awarded LSU Health Sciences ... (REU) Site grant in the amount of $295,635. ... from diverse social and educational backgrounds, underrepresented in ... The project will provide students with training ... It will be led by Principal Investigator ...
(Date:4/23/2014)... 2014 Pregnant immigrants from Sub-Saharan Africa, Latin ... during pregnancy, according to new research from St. ... the British Journal of Obstetrics and Gynaecology ... rates among immigrants and native-born women in six ... Sweden, Spain (Catalonia and Valencia) and the United ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
Breaking Medicine News(10 mins):Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... not always connected, researchers say , , FRIDAY, May 2 ... disturbances experienced by Alzheimer,s disease patients and the sleep ... team from the University of Washington, in Seattle, found ... aren,t always connected. , The researchers studied 44 older ...
... Epidemiology Center have found that approximately one in ten ... medications during a given week. These findings will ... & Asian Society for Pediatric Research Joint Meeting in ... widely marketed in the U.S. but surprisingly little is ...
... following is,being issued today by SEIU -- Inter-Con ... unfair labor practice strike against,Inter-Con to defend their ... the,first-ever group of hospital security officers to strike. ... were trying to form a,union for better conditions., ...
... Australian researchers have unveiled a new immunotherapy technique ... to AIDS. Details of the simple, cost-effective ... journal PLoS Pathogens. , There is an overwhelming ... therapies are expensive, impractical, and often highly toxic. ...
... WARSAW, Ind., May 2 Zimmer Holdings, Inc.,(NYSE ZMH; ... the,Deutsche Bank Securities 33rd Annual Health Care Conference, in ... Time., A live webcast of the presentation can ... . The webcast will,be archived for replay following ...
... says , , FRIDAY, May 2 (HealthDay News) -- Heart failure ... cancer, a new study finds. , Indeed, people in the ... inability to supply the body with oxygen-carrying blood, had measures ... that are seen in people with advanced cancer, Dr. David ...
Cached Medicine News:Health News:Sleep Troubles Vary Between Alzheimer's Patients, Caregivers 2Health News:1 in 10 children using cough, cold medications 2Health News:First-Ever Group of Hospital Security Officers to Strike over Unfair Labor Practices, Walk out of Facilities Across California on May 6 2Health News:Suffering of Heart Failure Similar to Cancer 2Health News:Suffering of Heart Failure Similar to Cancer 3
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
... & Solutions offers a wide variety ... needs of healthcare professionals. Whether you ... prefer a dry scrub brush in ... brushes provide the flexibility and options ...
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
Medicine Products: